N4 Pharma PLC (AIM: N4P) has officially changed its name to Thalia Therapeutics plc, effective March 18, 2026.
Avacta to present new preclinical data on pre|CISION platform at AACR meeting
Avacta Group PLC has announced it will present new preclinical and translational data for its pre|CISION® platform at the 2026 American Association for Cancer Research (AACR) Annual Meeting, which will
Avacta Therapeutics (AIM: AVCT) Phase 1 study opening for AVA6103
Avacta announces opening of Phase 1 trial for second pipeline asset, FAP-Exd (AVA6103) a sustained-release pre|CISION® exatecan peptide-drug conjugate Specialty U.S. oncology centers open for recruitment in Virginia and Texas
Shares surge 13% as mystery investor backs SkinBioTherapeutics
SkinBioTherapeutics PLC (AIM: SBTX) shares rose sharply after a regulatory filing revealed a major increase in ownership by investors Mark H Dixon and Diana Dixon.
Abingdon Health plc (AIM: ABDX) $2.5m Contract for clinical self-test development
$2.5m Contract Award for development of clinical self-test
Poolbeg Pharma (AIM: POLB) Appointment of Dr Adrian Kilcoyne to SAB
Appointment of Dr Adrian Kilcoyne to Scientific Advisory Board
Six Small Caps, PYC, KEN, FAR, ECR, FMET, PALM, Catalysts Move the Price
The last twelve months have been a reminder that small-cap investing is rarely linear. Shares can drift for months, then reprice in a matter of weeks when the right combination
N4 Pharma plc (AIM: N4P) CEO Appointment & Name Change Thalia Therapeutics
CEO Appointment, Strategic Update and Name Change to Thalia Therapeutics
Avacta Therapeutics (AIM: AVCT) PreCISION payload delivery advantage over ADC
Avacta’s pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis
Trellus Health plc shares soar 125% on Johnson & Johnson contract extension
Trellus Health plc (AIM: TRLS) shares surged 125% in early trading after the company announced a six-month contract extension with Johnson & Johnson Health Care Systems for its Trellus Elevate
SkinBioTherapeutics plc shares plunges over 40% after “alarming” investor update
SkinBioTherapeutics (AIM: SBTX), shares plunged more than 40% on Monday, extending losses after a 50% fall on Friday, following what the company described as an alarming update to investors.
SkinBioTherapeutics shares sink 30% on CEO departure and management reshuffle
SkinBioTherapeutics plc (AIM: SBTX), shares fell around 30% after the skin health-focused life sciences company announced the resignation of its chief executive officer, Stuart Ashman.